Telix points to 'promising' 13-month survival rate in phase 2 brain cancer radiopharma study
Telix Pharmaceuticals has pointed to “promising efficacy” for its radiation therapy in a small, single arm study of patients with brain cancer.
Telix Pharmaceuticals has pointed to “promising efficacy” for its radiation therapy in a small, single arm study of patients with brain cancer.
